The role of ABCG2 in modulating responses to anti-cancer photodynamic therapy

被引：18

作者：

Khot, M. Ibrahim ^{[1
]}

Downey, Candice L. ^{[1
]}

Armstrong, Gemma ^{[1
]}

Svavarsdottir, Hafdis S. ^{[1
]}

Jarral, Fazain ^{[1
]}

Andrew, Helen ^{[1
]}

Jayne, David G. ^{[1
]}

机构：

[1] Univ Leeds, St Jamess Univ Hosp, Sch Med, Leeds, W Yorkshire, England

来源：

PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY | 2020年 / 29卷

基金：

英国惠康基金;

关键词：

Photodynamic therapy; Photosensitisers; ABCG2; BCRP; CANCER RESISTANCE PROTEIN; NF-KAPPA-B; 5-AMINOLEVULINIC ACID; PROTOPORPHYRIN-IX; TRANSPORTER ABCG2; LUNG-CANCER; CHLORIN E6; IN-VITRO; CISPLATIN RESISTANCE; MULTIDRUG-RESISTANCE;

D O I：

10.1016/j.pdpdt.2019.10.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The ATP-binding cassette (ABC) superfamily G member 2 (ABCG2) transmembrane protein transporter is known for conferring resistance to treatment in cancers. Photodynamic therapy (PDT) is a promising anti-cancer method involving the use of light-activated photosensitisers to precisely induce oxidative stress and cell death in cancers. ABCG2 can efflux photosensitisers from out of cells, reducing the capacity of PDT and limiting the efficacy of treatment. Many studies have attempted to elucidate the relationship between the expression of ABCG2 in cancers, its effect on the cellular retention of photosensitisers and its impact on PDT. This review looks at the studies which investigate the effect of ABCG2 on a range of different photosensitisers in different pre-clinical models of cancer. This work also evaluates the approaches that are being investigated to address the role of ABCG2 in PDT with an outlook on potential clinical validation.

引用

页数：13

共 118 条

[1] Hypericin in cancer treatment: more light on the way [J].

Agostinis, P ;

Vantieghem, A ;

Merlevede, W ;

de Witte, PAM .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2002, 34 (03) :221-241

[2]

Allen JD, 2002, MOL CANCER THER, V1, P417

[3] Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro [J].

An, Ran ;

Hagiya, Yuichiro ;

Tamura, Ai ;

Li, Shanshan ;

Saito, Hikaru ;

Tokushima, Daisuke ;

Ishikawa, Toshihisa .

PHARMACEUTICAL RESEARCH, 2009, 26 (02) :449-458

[4]

[Anonymous], [No title captured]

[5]

[Anonymous], [No title captured]

[6] A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells [J].

Arambula, Jonathan F. ;

Sessler, Jonathan L. ;

Siddik, Zahid H. .

MEDCHEMCOMM, 2012, 3 (10) :1275-1281

[7] Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells [J].

Baglo, Yan ;

Liang, Barry J. ;

Robey, Robert W. ;

Ambudkar, Suresh V. ;

Gottesman, Michael M. ;

Huang, Huang-Chian .

CANCER LETTERS, 2019, 457 :110-118

[8] Differential sensitivity in cell lines to photodynamic therapy in combination with ABCG2 inhibition [J].

Barron, Gemma A. ;

Moseley, Harry ;

Woods, Julie A. .

JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 2013, 126 :87-96

[9]

Baskaran Rengarajan, 2018, Biomater Res, V22, P25

[10] Specific inhibition of the ABCG2 transporter could improve the efficacy of photodynamic therapy [J].

Bebes, Attila ;

Nagy, Tuende ;

Bata-Csoergo, Zsuzsanna ;

Kemeny, Lajos ;

Dobozy, Attila ;

Szell, Marta .

JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 2011, 105 (02) :162-166

← 1 2 3 4 5 6 7 8 9 10 →